



**A retrospective audit of maternal and fetal outcomes associated  
with fetal macrosomia ( $\geq 4000$  g) at King Edward VIII Hospital from  
1<sup>st</sup> July 2012 to 1<sup>st</sup> July 2013**

**Dr Kiresha Naicker**

**Submitted in Partial Fulfillment of the Academic Requirement for the Degree of the  
Fellowship of the College of Obstetrics and Gynaecology of South Africa FCOG (Part II)**

## Declaration

### **Declaration**

I, **Dr Kiresha Naicker**, declare that this dissertation entitled "A retrospective audit of maternal and fetal outcomes associated with fetal macrosomia ( $\geq 4000$  g) at King Edward VIII Hospital from 1<sup>st</sup> July 2012 to 1<sup>st</sup> July 2013 is my original work and has not been submitted in any form to another university. Where use was made of the work of others, it has been duly acknowledged in the text.

### **Candidate**


**Dr Kiresha Naicker**

Signature 

Department of Obstetrics and Gynaecology  
Nelson R. Mandela School of Medicine  
University of KwaZulu-Natal, Durban

### **Supervisor**

**Dr HC Maise**

Signature 

Department of Obstetrics and Gynaecology  
Nelson R. Mandela School of Medicine  
University of KwaZulu-Natal, Durban

### **Co-supervisor**

**Dr HM Sebitloane**

Signature 

Department of Obstetrics and Gynaecology  
Nelson R. Mandela School of Medicine  
University of KwaZulu-Natal, Durban

## **Dedication**

**I would like to dedicate my dissertation to:**

**First and foremost to God Almighty for granting me the knowledge, wisdom and strength to complete this study.**

### **My Parents**

**My father, Dr Ramakrishnan Soobramoney Naicker. Without his inspiration, guidance and support I may not be the person I am today. For being my best teacher.**

**My mother, Renuka Devi Naicker who has always been a constant source of love, motivation and strength during my moments of despair and discouragement.**

### **My siblings**

**Revesh and my dearest sister Sanisha for their patience, encouragement and eternal love. You have been my greatest supporter.**

**My beloved brother Renesh who is my best friend, angel and inspiration. I wish I will be born being your sister in every life...**

### **My grandparents**

**For all their love and blessings throughout my life.**

### **My precious pets**

**For giving me such joy and wonderful memories.**

## **Acknowledgements**

I wish to express my appreciation and thanks to my supervisors Dr HC Maise and Dr HM Sebitloane, Department of Obstetrics and Gynaecology based at Nelson R Mandela School of Medicine, University of KwaZulu Natal for his/her expert advice, support and encouragement from the initiation of this dissertation to its completion.

I thank the following regulatory bodies for permission to conduct the study:

1. The KZN Department of Health
2. The Biomedical Research Ethics Committee (BREC), UKZN for ethical approval to conduct the study (BE: 055/15)
3. The Manager, King Edward VIII Hospital
4. Department of Postgraduate Research and Education

## List of Figures

<b>Box 1:</b> Maternal complications	3
<b>Box 2:</b> Neonatal complications	3

## List of Tables

<b>Table 1:</b> Patient demographics	15
<b>Table 2:</b> Laboratory variables	16
<b>Table 3:</b> Obstetric condition at presentation	17
<b>Table 4:</b> Socio-economic details of the mothers	18
<b>Table 5:</b> Co-morbidities	18
<b>Table 6:</b> Indications for CS	20
<b>Table 7:</b> Complications experienced by mothers following delivery of macrosomic babies either by normal vaginal delivery or caesarean delivery	21
<b>Table 8:</b> Frequency of macrosomia according to birth weight (data presented as number and percentage)	22
<b>Table 9:</b> Neonatal complications observed in macrosomic babies	23

## List of Abbreviations

<b>CS</b>	Caesarean Section
<b>RPR</b>	Rapid Plasma Reagin
<b>WHO</b>	World Health Organisation
<b>BMI</b>	Body Mass Index

<b>List of contents</b>	Page no
Title page	i
Declaration	ii
Dedication	iii
Acknowledgements	iv
List of Figures	v
List of Tables	v
List of abbreviations	v
List of contents	vi
Abstract	ix

## **Chapter One: Introduction**

1.0 Background	1
1.1 Prevalence of macrosomia	1
1.2 Maternal complications	3
1.2.1 Prolonged labour	3
1. 2.2 Operative delivery	4
1.2.3 Postpartum haemorrhage	4
1.2.4 Perineal trauma	4
1.3 Fetal and Neonatal complications	4
1.3.1 Shoulder dystocia	5
1.3.2 Birth trauma	5
1.3.3 Brachial Plexus Injury	5
1.3.4 Skeletal Injuries	6
1.3.5 Chorionamnionitis	6
1.3.6 Meconium Aspiration	6
1.3.7 Perinatal Asphyxia	7
1.3.8 Poor Apgar Scores	7

1.3.9 Neonatal hypoglycemia	7
1.3.9.1 Intrauterine Death	7
1.3.9.2 Neonatal and infant mortality	8
1.4 Long term complications	9
1.5 Prenatal diagnosis of fetal macrosomia	9
1.6 Management of fetal macrosomia	10
1.7 Rationale	11
1.8 Objectives	11
1.9 Hypothesis	11
<b>Chapter 2: Methodology</b>	
2.0 Study location	12
2.1 Study period	12
2.2 Study design	12
2.3 Study population	12
2.4 Sample size	12
2.5 Inclusion criteria	12
2.6 Exclusion criteria	12
2.7 Data collection	12
2.8 Statistical planning	13
2.9 Ethical consideration	13
<b>Chapter 3: Results</b>	
3.0 Demographic details	14
3.1 Laboratory variables	16
3.2 Obstetric conditions at presentation	16
3.3 Socioeconomic status of the mothers	17
3.4 Previous macrosomic history	18
3.5 Co-morbidities	18
3.6 Maternal outcomes	19
3.6.1 Mode of delivery	19

3.6.2 Maternal complications	20
3.7 Neonatal outcome	21
<b>Chapter 4: Discussion</b>	
4.0 Discussion	24
4.1 Limitations	26
4.3 Conclusions	26
4.4 Recommendations	26
<b>Chapter 5: References</b>	27
<b>Chapter 6: Annexure</b>	44
Annexure: 1 Data sheet	44



## **Abstract**

### **Introduction**

Pregnancies with a macrosomic fetus are high-risk pregnancies and the incidence appears to be rising. The aim of our research was to identify the clinical profile of mothers who gave birth to macrosomic infants, and to study the maternal and neonatal complications associated with delivering infants with a birth weight of 4000 grams or greater.

### **Methods**

Retrospective study involving a total of 238 deliveries of macrosomic babies from 1<sup>st</sup> July 2012 to 1<sup>st</sup> July 2013 at King Edward VIII Hospital, Durban. The study concerned the clinical profile of mothers who give birth to a macrosomic infant including the risk factors, mode of delivery and the incidence of maternal and perinatal complications. Data was analyzed using SPSS (version 23).

### **Results**

Macrosomia occurred in 3.4% of all deliveries. Main risk factors for macrosomia were previous history of macrosomia, male sex, hypertensive disorders of pregnancy, body mass index  $\geq 25$ , para 1 and 2, diabetes and higher gestational age at delivery. Majority of macrosomic infants were born to non-diabetic women in our audit.

Moreover, macrosomia increased delivery complications for both mothers and newborns. Neonatal complications included: shoulder dystocia was noted in 2.4%, respiratory distress (3.4%) neonatal jaundice (5.1%), and admission to nursery was noted in 99.6% of the cases and for a median duration of 1 day (range 1–11 days). Hypoglycemia complicated 18.6% of deliveries. Twenty (8.4%) infants were resuscitated. The stillbirth rate was 0.4%. Maternal complications included prolonged labour (5.9%), caesarean delivery (64.3%), post-partum haemorrhage documented in 25.2% of cases and perineal tears and cervical lacerations was noted in 34.1% of vaginal deliveries. There was a significant difference in the percentage of neonatal morbidity in the infants delivered vaginally compared to caesarean delivery (48.2% vs 7.8%;  $p < 0.02$ ). No maternal deaths occurred.

### **Conclusion**

The prevalence of macrosomia was 3.4%. Main risk factors for macrosomia were previous history of macrosomia, male sex, hypertensive disorders of pregnancy, body mass index  $\geq 25$ , para 1 and 2, diabetes and higher gestational age at delivery. Mother and neonate are at increased risk of complications.

## **Introduction**

### **1.0 Background**

Macrosomia is a term used to describe a large fetus or neonate weighing  $\geq 4000\text{g}$  at term<sup>1</sup>. The Pedersen's hypothesis, which was suggested more than sixty years ago, links fetal macrosomia to the transplacental passage of excessive maternal glucose, which leads to fetal hyperglycaemia and excessive fetal insulin release<sup>2</sup>. Since its introduction, the Pedersen hypothesis has been further extended by other investigators and accepted as the pathophysiologic basis for increased risk of macrosomia among infants of women with diabetes during pregnancy<sup>3-5</sup>.

There is no universally accepted definition of fetal macrosomia. While some clinicians believe that infants with birth weight  $\geq 4000\text{ g}$  or above the 90<sup>th</sup> percentile for the population and sex-specific growth curve can be said to be macrocosmic, others have used birth weight  $\geq 4500\text{ g}$ <sup>6,7</sup>. The American College of Obstetricians and Gynecologists (ACOG) defined macrosomia as birth-weight over 4,000 g irrespective of gestational age or greater than the 90<sup>th</sup> percentile for gestational age after correcting for neonatal sex and ethnicity<sup>8</sup>. There has been further interest in the group of infants whose birth weight exceeds 5000 g<sup>9</sup>.

### **1.1 Prevalence of macrosomia**

The prevalence of fetal macrosomia varies between 0 -15%<sup>10</sup> but the higher prevalence have been reported in higher income countries compared to low and middle income countries<sup>11,12</sup>. The prevalence of macrosomia varies in sub-Saharan countries between 1.9 % in Ethiopia and 14.6 % in Nigeria<sup>13</sup>. In Cameroon, its prevalence in 1995 was 6.4 %<sup>14</sup>. In South Africa, the prevalence was 3.4% in 1995<sup>15</sup>. A study from Denmark indicated an increase in the frequency of macrosomia from 16.7% in 1990 to 20.0% in 1999<sup>16</sup>.

A number of risk factors associated with macrosomia have been identified, and include maternal body mass index, weight gain, advanced maternal age, multiparity, diabetes, and gestational age >41 weeks<sup>17, 18</sup>. However, it is well known that prediction based on clinical risk factors alone and together with first trimester nuchal translucency and biochemical markers (free beta-human chorionic gonadotropin and pregnancy associated plasma protein A has a very low positive predictive value<sup>19, 20</sup>. Non-modifiable factors include genetics, fetal sex, parity, maternal age and height. Modifiable factors include pre-gestational maternal anthropometric characteristics (BMI), gestational weight gain and maternal glucose metabolism.

Race and ethnicity are associated with macrosomia<sup>1, 21</sup>. The incidence of macrosomia varies according to ethnicity, and is lower in the Chinese population. This difference in birth weight distribution is likely due to the genetic differences and anthropometric discrepancies between populations. From a recent study, the incidence of macrosomia in Chinese population was reported to be only 3.4%<sup>21</sup>.

Factors associated with fetal macrosomia include genetics, duration of gestation, presence of gestational diabetes, and diabetes mellitus types I and II. Genetic, racial, and ethnic factors influence birth weight and the risk of macrosomia<sup>22</sup>. Maternal diabetes is one of the strongest risk factors associated with giving birth to an infant that is considered large for gestational age. Pre-gestational and gestational diabetes result in fetal macrosomia in as many as 50% of pregnancies complicated by gestational diabetes and in 40% of those complicated by type 1 diabetes mellitus. Esseland Opai-Tetteh(1995) showed that the risk of macrosomia increases with maternal age<sup>15</sup>.

Primary concern about the birth of a macrosomic fetus is adverse neonatal outcomes including stillbirth and neonatal mortality secondary to birth asphyxia, shoulder dystocia, birth injury, metabolic disorders, and meconium aspiration syndrome. The occurrence of these unfavourable outcomes and their risks factors have been widely studied<sup>23 - 25</sup>.

Similarly, maternal complications such as increased risk of caesarean delivery, postpartum haemorrhage and perineal lacerations are increased in the setting of fetal macrosomia<sup>17, 26–28</sup>. Maternal and neonatal complications are shown in boxes 1 and 2.

Box 1

<b>Maternal complications</b>
<ul style="list-style-type: none"><li>• Prolonged labour</li><li>• Operative delivery</li><li>• Postpartum haemorrhage</li><li>• Perineal trauma</li></ul>

Box 2

<b>Neonatal complications</b>
<ul style="list-style-type: none"><li>• Shoulder dystocia</li><li>• Birth trauma</li><li>• Brachial plexus injury</li><li>• Skeletal injuries</li><li>• Chorioamnionitis</li><li>• Aspiration of meconium</li><li>• Perinatal asphyxia</li><li>• Poor Apgar scores</li><li>• Neonatal hypoglycemia</li><li>• Intrauterine fetal death</li></ul>

## **1.2 Maternal complications**

### **1.2.1 Prolonged labour**

The duration of labour is more prolonged for women carrying macrosomic babies, and the risk is increased with increasing birth weight<sup>29</sup>. Both the first and second stages of labour are longer than for normosomic pregnancies, and arrest of descent in the second stage of labour can occur secondary to macrosomia<sup>30</sup>. In a study of macrosomic infants weighing more than 4,500 g, the risk of shoulder dystocia is higher when the second stage is longer than 2 hours, with a crude odds ratio (OR) of 1.17 (95% confidence interval [CI] 0.82–1.66)<sup>24</sup>. Prolonged labour associated with macrosomia is, in turn, a contributor to other maternal complications, including operative delivery and postpartum haemorrhage.

## **1.2. 2 Operative deliveries**

The incidences of vaginal operative delivery and caesarean section are higher for macrosomic infants<sup>24, 29, 31, 32</sup>. The overall rate of caesarean section in babies with a birth weight >4,000 g varies widely between different studies and ranges from 14% to 44%<sup>33, 34</sup>. The risk of caesarean section escalates with increasing birth weight, and the proportion of vaginal instrumental delivery decreases with increasing birth weight<sup>29, 31</sup>. The increased risk of caesarean section is a consistent finding in different countries and in different ethnic groups, and the odds are particularly high for primiparous mothers<sup>35</sup>. In macrosomic births, the risk of shoulder dystocia is associated with the need for vaginal instrumental delivery<sup>24</sup>.

## **1.2.3 Postpartum haemorrhage**

Postpartum haemorrhage occurs more commonly following delivery of macrosomic babies<sup>29, 36</sup> and again, the risk increases with increasing birth weight<sup>31</sup>.

## **1.2.4 Perineal trauma**

The risk of perineal tears increases 1.5-fold to 2-fold in cases of macrosomia<sup>37, 38</sup>. Some investigators suggest that the incidence of major perineal tear rises significantly with greater birth weight<sup>39</sup> but this has been refuted<sup>31</sup>. The risk appears to be higher in Asian, Filipino, and Indian women than in Caucasian women<sup>37</sup>. Such differences in the anatomy of the perineum, such as perineal body length and thickness among different ethnic groups, may be contributing factors<sup>40</sup>. Major perineal trauma, including third and fourth degree tear, can cause significant long-term anal incontinence, which can have a negative impact on the woman's quality of life.

## **1.3 Fetal and neonatal complications**

Although the literature frequently and consistently demonstrates an increase in perinatal morbidity and mortality with increasing birth weight, the overall incidence of neonatal complications remains low<sup>40</sup>.

### **1.3.1 Shoulder dystocia**

The incidence of shoulder dystocia ranges between 0.58% and 0.70% in Caucasians<sup>41</sup>. It also appears to vary with ethnicity, with an incidence of only 0.3% in the Chinese population<sup>42</sup>. It has been reported consistently in the literature that the risk of shoulder dystocia escalates with increasing birth weight<sup>42–44</sup>. However, the incidence of shoulder dystocia in different birth weight groups varies widely between studies. In a recent study in Norway, the incidence was approximately 1%, 2%, 4%, and 6% for birth weights of 4,000–4,199 g, 4,200–4,399 g, 4,400–4,599 g, and  $\geq 4,600$  g<sup>44</sup>, respectively, whereas another study reported an incidence of over 20% when the birth weight was above 4,500 g. Nevertheless, despite such an association, half or even more of the births complicated by shoulder dystocia occur in babies with a birth weight less than 4,000 g<sup>42</sup>.

### **1.3.2 Birth trauma**

The incidence of birth trauma, namely brachial plexus and skeletal injuries, increases with rising birth weight<sup>25, 29</sup>.

### **1.3.3 Brachial plexus injury**

Congenital brachial plexus injury is defined as flaccid paresis of an upper extremity due to traumatic stretching of the brachial plexus at birth, with passive greater than active range of motion. The incidence varies between countries and is approximately 1.5 cases per 1,000 live births<sup>42, 45</sup>.

Brachial plexus injury is characteristically related to shoulder dystocia; however, such complications can occur following normal spontaneous vaginal delivery and caesarean section<sup>46</sup>. Both excessive exogenous traction and strong endogenous pushing forces contribute to brachial plexus injury BPI<sup>47</sup>. The second most important risk factor for BPI is heavy birth weight<sup>43</sup>, which is associated with a 14-fold increase in risk<sup>45</sup>. In one study, the prevalence of BPI progressively increased with infant weight, occurring in only 3% of neonates in the 4,500–5,000 g group and 6.7% in the  $>5,000$  g group<sup>48</sup>.

Moreover, the risk is further increased when macrosomia and gestational diabetes coexist, with an adjusted OR of 42 (95% CI 4.05–433.64)<sup>43</sup>.

It has also been reported that BPI among infants weighing  $\geq 4,000$  g is more likely to be severe and persistent than in the normosomic group<sup>49</sup>. Because the two main risk factors for congenital BPI, i.e., shoulder dystocia and macrosomia, are not easily predictable, it is difficult to foresee and prevent its occurrence<sup>47</sup>.

#### **1.3.4 Skeletal injuries**

Skeletal injuries commonly occur in the presence of shoulder dystocia and are associated with large infants<sup>24, 50</sup>. Fracture of the clavicle is five times more common in macrosomic infants, and occurs more often in vaginal delivery than in caesarean section<sup>40, 51</sup>. Humeral fractures are less frequent, but also occur in big babies. Gregory et al in 1998 analysed neonatal complications following shoulder dystocia and reported that, unlike brachial plexus injury, the risk of having skeletal injuries in macrosomic infants is not higher than in those with normal birth weight<sup>40</sup>. Clavicular fractures are usually managed conservatively and the outcome is most often benign, with complete recovery and no associated neurologic complications. Humeral fractures are managed mainly by closed reduction followed by splinting or traction techniques, and usually do not have long-term sequelae.

#### **1.3.5 Chorioamnionitis**

Significant maternal and neonatal complications can result from the birth of a macrosomic infant, and includes chorioamnionitis. The risk of chorioamnionitis slowly and steadily increases as birth weight increases, and the ORs are 1.94, 2.17, and 2.42 for birth weight groups of 4,000–4,499 g, 4,500–4,999 g, and  $\geq 5,000$  g<sup>17</sup>, respectively.

#### **1.3.6 Aspiration of meconium**

Aspiration of meconium is a risk associated with macrosomia<sup>29, 32</sup>. Again, the risk increases with rising birth weight. The ORs are 1.28, 1.65, and 2.61 for babies with birth weights of 4,000–4,499 g, 4,500–4,999 g, and  $>5,000$  g, respectively<sup>29</sup>. However, other investigators reported that the association was not statistically significant<sup>23</sup>.

### **1.3.7 Perinatal asphyxia**

The risk of macrosomic neonates suffering from perinatal asphyxia increases 2–4-fold compared with that in normosomic infants<sup>23, 40</sup>. The odds of perinatal asphyxia increase considerably with rising birth weight; in one study, the OR was 2.3 if birth weight was 4,500–4,999 g and increased further to 10.5 if birth weight was >5,000 g<sup>25</sup>.

### **1.3.8 Poor Apgar scores**

There are reports that Apgar scores are poor in infants with macrosomia. The greater the birth weight, the higher the risk of low Apgar scores<sup>25, 29</sup>. Boulet et al in 2003 showed the OR for a 5-minute Apgar score  $\leq 6$  was 1.65 and 3.49 for infants with birth weight 4,500–4,999 g and >5,000 g, respectively, whereas that for a 5-minute Apgar score  $\leq 3$  was even higher, with corresponding ORs of 2.01 and 5.<sup>20,29</sup> Furthermore, the risk of a low Apgar score is eight times higher in macrosomic babies when the delivery is complicated by shoulder dystocia<sup>24</sup>. In contrast, Weissmann-Brenner et al in 2012 could not demonstrate any statistically significant difference in low Apgar scores between normal and big babies<sup>31</sup>.

### **1.3.9 Neonatal hypoglycemia**

The risk of neonatal hypoglycemia is higher in heavy babies<sup>43</sup>, and the risk increases with increasing birth weight. Neonates with a birth weight >4,500 g had a seven-fold higher risk of having neonatal hypoglycemia, compared with those appropriate for gestation age<sup>31</sup>. This risk further increases in the presence of gestational diabetes. Infants with a birth weight  $\geq 4,000$  g delivered by no diabetic mothers had a 2.4% risk of neonatal hypoglycemia, whereas those whose mothers had gestational diabetes had an incidence of 5.3%<sup>43</sup>.

#### **1.3.9.1 Intrauterine fetal death**

Macrosomia has been consistently shown to be associated with a 2–3-fold increase in intrauterine fetal death<sup>52</sup>.



Zhang et al in 2008 showed that birth weights of 4,000–4,499 g were not at increased risk of mortality compared with those born at 3,500–3,999 g; however, those born at 4,500–4,999 g had a significantly increased risk of stillbirth (OR 2.7, 95% CI 2.2–3.4) and the risk rose dramatically with a birth weight  $\geq 5,000$  g (OR 13.2, 95% CI 9.8–17.7)<sup>25</sup>. Because maternal diabetes is closely related to macrosomia and fetal death, Mondestin et al in 2002 addressed this complex interaction and showed that the fetal death rate increased in macrosomic fetuses in both diabetic and non-diabetic pregnancies, but the cut off birth weight was different, being  $\geq 4,250$  g in non-diabetic women and  $\geq 4,000$  g in their diabetic counterparts<sup>53</sup>.

### **1.3.9.2 Neonatal and infant mortality**

Numerous epidemiologic studies have shown a distinct relationship between birth weight and neonatal and infant mortality, and have consistently demonstrated a reverse J pattern of weight-specific mortality in all populations, where the mortality rates increase at the extremes of birth weight<sup>54</sup>. Compared with a normosomic group of infants with a birth weight of 3,000–3,999 g, babies with a birth weight  $> 5,000$  g had a 2–3-fold increase in risk of neonatal death, and a 1.6–2.0-fold increased risk of post neonatal and infant mortality, respectively. Such an association was not identified in babies with a birth weight of 4,000–4,999 g<sup>29</sup>. However, a recent study by Zhang et al in 2008, which included close to 6 million births from the USA, showed that neonates with a birth weight  $> 4,500$  g also had a higher early neonatal death rate (OR 1.8), but there was no increase in late or post neonatal death<sup>25</sup>. Early, late, and post neonatal deaths were all significantly increased in those weighing  $\geq 5,000$  g, with ORs of 6.4, 5.2, and 2.3, respectively. The leading cause of early neonatal death in macrosomic babies was asphyxia.

Sudden infant death syndrome is another concern for macrosomic babies, but the current data are conflicting. The majority of post neonatal deaths reported by Zhang et al in 2008 were due to sudden infant death syndrome. Infants with a birth weight  $\geq 5,000$  g have a more than 2-fold increase in risk<sup>25</sup>. However, such a detrimental effect was not identified in other studies, and excessive intrauterine growth (birth weight  $> 90$ th percentile) has even been shown to have a protective role in sudden infant death syndrome<sup>55</sup>.

#### **1.4 Long-term complications**

The Barker hypothesis explains the concept of fetal programming in utero, such that events during early development have a profound impact on the risk for development of future adult disease. Birth weight has been shown to be predictive of a number of adult diseases, such as hypertension, obesity, and insulin resistance<sup>56</sup>. Alternative explanations for the association between fetal growth and later diseases, mainly genetic factors, have also been proposed.

Increased birth weight has been shown to have a positive association with overweight, insulin resistance, and metabolic syndrome in later life. The risk of developing metabolic syndrome in childhood is highest when there is coexistence of macrosomia and maternal gestational diabetes, and is comparatively less marked in the group with macrosomia alone<sup>57</sup>.

Interestingly, breast cancer has been found to be associated with high birth weight in numerous studies<sup>58</sup>. Those with particularly high birth weight ( $\geq 4,500$  g) had the most pronounced elevation in risk (OR 3.10, 95% CI 1.18–7.97). It is postulated that this association is mediated in part by hormonal mechanisms that positively influence fetal growth and mammary gland development.

#### **1.5 Prenatal diagnosis of fetal macrosomia**

Prenatal estimation of fetal weight is notoriously known to be inaccurate, with errors exceeding 10% of the actual birth weight<sup>59</sup>. In fact, sonographic estimates of birth weight are no better than clinical assessment. The sonographic detection of macrosomic infants  $>4,000$  g is even more unreliable, with a low sensitivity, low positive predictive value<sup>60</sup>. Different formulae for estimated fetal weight have been evaluated and the prediction of macrosomia is poor. The mean detection rates for fetuses with a birth weight of  $\geq 4,000$  g,  $\geq 4,300$  g, and  $\geq 4,500$  g were 29%, 24%, and 22%, respectively, and false positive rates were 12% (for  $\geq 4,300$  g) and 7% (for  $\geq 4,500$  g)<sup>61</sup>. Moreover, many researchers have developed additional assessment methods to improve the detection of macrosomia, including two-dimensional and three-dimensional assessment of fetal subcutaneous and soft tissue.

However, these methods are more time-consuming and technically demanding. Recently, a new formula has been shown to be superior to the traditional formulae for prediction of macrosomia, where 78% of estimates fell within  $\pm 5\%$  of the actual weight at birth, 97% within  $\pm 10\%$ , and 100% within  $\pm 15\%$  and  $\pm 20\%$ <sup>62</sup>.

### **1.6 Management of fetal macrosomia**

The management of suspected fetal macrosomia continues to be an obstetric challenge. This is due to the inaccuracy of prenatal clinical or sonographic diagnosis as discussed above, and also because of the difficulty in prediction of its complications during labour, in particular, the risk of shoulder dystocia<sup>42, 63</sup>.

The most effective way to manage macrosomia is probably by prevention. Two of the most important risk factors for macrosomia which can be modifiable are maternal obesity and gestational diabetes. The risk of macrosomia increases with the severity of maternal obesity<sup>64</sup>. Weight loss and also reduction in body mass index between the first and second pregnancies can reduce the risk of large for gestational age births<sup>65</sup>. Achieving optimal glycaemic control in diabetic women, especially postprandial glucose control, can also prevent macrosomia and reduce the incidence of shoulder dystocia and birth trauma<sup>66</sup>.

The idea of inducing labour for suspected macrosomia before the baby grows too big, with an aim to reduce operative deliveries and birth trauma, has not been supported by clinical evidence. Induction of labour for suspected macrosomia in non-diabetic women has not been shown to improve either maternal or neonatal outcome<sup>67</sup>. On the other hand, because women with diabetes have a higher risk of shoulder dystocia and birth trauma, the National Institute for Health and Care Excellence guideline currently suggests that pregnant women with diabetes should be offered elective birth by induction of labour after 38 weeks of gestation<sup>68</sup>.

Whether elective caesarean section should be performed to prevent BPI is another controversial issue. It has been estimated that 443 caesarean sections are required to prevent one permanent BPI in diabetic women with an estimated fetal weight >4,500 g, and an exceedingly high number (3,695) of caesarean sections are needed to prevent one permanent BPI in the non-diabetic population<sup>69</sup>.

The Royal College of Obstetricians and Gynaecologists and the American College of Obstetricians and Gynaecologists recommend elective caesarean delivery in diabetic and non-diabetic women with estimated fetal weight >4,500 g and >5,000 g, respectively<sup>41, 70</sup>. However, these guidelines may not be appropriate for the Asian population because the birth weight cut-off is too high<sup>42</sup>.

### **1.7 Rationale**

Since there has not been any study conducted on macrosomic newborns in Kwa Zulu Natal, the present study will help to understand the prevalence, risk factors and maternal, fetal and neonatal complications of macrosomic newborns in the region. It will also draw attention of policy makers to improve the maternal and child health status in the region along with helping the fight for the present obstetrics challenges in Kwa Zulu Natal. It will therefore contribute to the academic discourse on reproductive health within the discipline of public health and most likely will come up with the ideas for future research on the subject. Considering increased risks of complications related to delivery of macrosomic fetuses the aim of this research was to determine the incidence, risk factors and perinatal outcome associated with giving birth to macrosomic babies weighing four or more kilograms.

### **1.8 Objectives**

1. The profile of pregnant women with risk factors for fetal macrosomia
2. The maternal outcome associated with fetal macrosomia
3. The fetal outcome associated with fetal macrosomia

### **1.9 Hypothesis**

Fetal macrosomia is associated with an increased risk of maternal and fetal complications

## **Methodology**

### **2.0 Study Location**

King Edward VIII Hospital, Durban, Kwazulu Natal.

### **2.1 Study period**

1<sup>st</sup>July 2012 to 1<sup>st</sup>July 2013.

### **2.2 Study Design**

A retrospective chart audit. All information was obtained from chart reviews.

### **2.3 Study Population**

All women who delivered macrosomic infants at King Edward VIII Hospital from 1<sup>st</sup>July 2012 to 1<sup>st</sup>July 2013 were included.

### **2.4 Sample Size**

Using a single proportion formula with degree of confidence of 1.65 and prevalence of 3.4% as according to the previous study <sup>15</sup>, 50 mothers were required as study subjects. However a total of 238 mothers were enrolled in this study.

### **2.5 Inclusion Criteria**

Singleton pregnancies

Gestational age of term pregnancies (37 to 42 weeks)

### **2.6 Exclusion Criteria**

Multiple pregnancies

Pregnancies complicated by intrauterine growth restriction

Patients with incomplete data were excluded

### **2.7 Data collection**

Demographic, obstetrical characteristics and maternal, fetal, neonatal, and pregnancy outcomes of macrosomic infants were recorded in a structured format

The following parameters were recorded in a structured format (Appendix 1).

- Demographic profiling
- Co morbidities
- Socio-economic status
- Past obstetric history
- Maternal complications
- Neonatal complications.
- Length of mothers stay in hospital

BMI was categorized in the following groups, according to the Guidelines of American Clinics for the identification, evaluation and treatment of obesity and overweight in adults: normal weight (BMI 18.5–24.9 kg/m<sup>2</sup>), overweight (BMI 25–29.9 kg/m<sup>2</sup>) and obese (BMI  $\geq 30$  kg/m<sup>2</sup>)<sup>71</sup>. Age was grouped as follows: < 25 years, 25-35 years and > 35 years.

## **2.8 Statistical Planning**

Data were captured on a customised MS Excel spread sheet and analysed using SPSS version 23. The Pearson's correlation coefficient was utilised for the correlation between weight of the newborn and gestational age at delivery or neonatal complications. A p value <0.05 was considered significant.

## **2.9 Ethical Consideration**

Ethics approval was obtained from the University of KwaZulu Natal Biomedical Research Ethics Committee (BE: 055/15) for a retrospective review of data, analysis and publication.

## Results

### 3.0 Demographic data

There were 6932 deliveries during the one year study period. Of this 238 were macrosomic deliveries. The prevalence of macrosomic newborns was 3.4%. The mean age of mothers that had macrosomic babies was  $26.6 \pm 5.8$  (range: 14 – 41) years. Eighty nine (37.4%) mothers were aged  $\leq 20$  years, 122 (51.3%) were aged between 21 – 30 years, 26 (10.9%) were aged between 31 – 40 years and one (0.4%) was aged between 41-50 years. The maximum frequency of macrosomic births occurred in women in the 21-30 year age group. There was no significant difference in the mean birth weight of macrosomic babies with shoulder dystocia and those without shoulder dystocia ( $4180.7 \pm 278.7\text{g}$  vs.  $4204.0 \pm 188.6\text{g}$ ,  $P = 0.64$ ). Body mass index was categorized as follows: Two (0.8%) were of normal BMI, 90 (36.2%) mothers were overweight and 159 (63%) were obese.

The mean (SD) parity was  $1.3 \pm 1.2$  (range: 0 – 7). Seventy two (30.3%) of the mothers were para 0, 132 (55.5%) were between para 1 and para 2, 30 (12.6%) were between para 3 and para 4 and 4 (1.6%) between para 5 and para 7. The mean (SD) gravidity was  $2.4 \pm 1.3$  (range: 1 – 8). Two hundred and thirty four (98.3%) mothers attended antenatal care with a mean number of antenatal visits of  $6.6 \pm 2.5$  (range: 1 – 16). The mean gestational age at booking for antenatal care was  $21.3 \pm 7.4$  (range 4 – 40) weeks. The mean (SD) gestational age at delivery of 209 (87.8%) mothers was  $39.7 \pm 1.2$  (range: 37 – 42) weeks. In 29 (12.2%) mothers gestational age at delivery was 42+ weeks. (Table 1)

**Table 1: Patient demographic profiles**

<b>Variables</b>	<b>Number</b> <b>N=238</b>	<b>Percentages</b>
<b>Age (26.6 ± 5.8 (range: 14 – 41) years.</b>		
Age groups		
< 20	89	37.4
21-30	123	51.3
31 – 40	26	10.9
41 - 50	1	0.4
<b>Body mass index (35.6±6.4) range (24 - 61)</b>		
BMI groups		
Normal	2	0.8
Overweight	90	36.2
Obese	159	63.0
<b>Parity: 1.3 ± 1.2 (range: 0 – 7)</b>		
0	72	30.3
1 – 2	132	55.5
3 – 4	30	12.6
5 – 7	4	1.6
<b>Gravid 2.4 ± 1.3 (range: 1 – 8)</b>		
1 - 2	197	82.8
3 – 4	23	9.7
5 – 8	18	7.6
<b>Antenatal visits: 6.6 ± 2.5 (range: 1 – 16)</b>		
1 - 4	46	19.3
5 - 8	154	64.7
9 - 16	34	14.3
<b>Gestational age (weeks)</b>		
At booking 21.3 ± 7.4 (range 4 - 40)		
At term(n=209) 39.7 ± 1.2 (37 – 42)		
At post term (n=29) 42+		



### 3.1 Laboratory variables

The mean (SD) haemoglobin was  $10.9 \pm 1.2$  (range: 7.5- 14.5). Two hundred and thirty five (98.7%) was rhesus positive. The RPR was negative in 98.3% of the patients. One hundred and sixty (67.2%) were HIV negative.

**Table2: Laboratory variables**

<b>Variable</b>	<b>Number</b>	<b>Percentage</b>
	<b>n=238</b>	
<b>Haemoglobin:</b> (mean : $10.9 \pm 1.3$ ) (range: 7.5- 14.5)		
<b>Rhesus factor</b>		
Positive	235	98.7
Negative	3	1.3
<b>RPR</b>		
Positive	4	1.7
Negative	234	98.3
<b>HIV status</b>		
Negative	160	67.2
Positive	78	32.8

### 3.2 Obstetric condition at presentation

Table 3 lists the 95 (39.9%) mothers who presented with obstetric conditions: 3 (1.3%) mothers were diabetic and 2 (0.8%) mothers developed gestational diabetes but of the medical conditions in pregnancy, hypertensive complications were the main problem.

**Table 3: Obstetric condition at presentation**

<b>Obstetric condition at presentation</b>	<b>Frequency n=95</b>	<b>% of the total macrosomic population</b>
Diabetes	3	1.3
Gestational diabetes	2	0.8
Previous CS (x1 and 2 or more)	45	18.9
Hypertension complications of pregnancy (n=21)		
Pre-eclampsia	12	5.0
Gestational hypertension	9	3.8
Abruptio placenta	1	0.4
Multifibroid uterus	1	0.4
Breech	1	0.4
High body mass index	3	1.3
Termination of pregnancy	1	0.4
Tuberculosis	1	0.4
Advanced maternal age	4	1.7
Asthma	1	0.4
Polyhydramnios	5	2.1
Teenage pregnancy	6	2.5

### **3.3 Socio-economic variables of the mothers**

Majority of the mothers were single (90.3%); 14.3% were employed and 0.8% consumed alcohol. Among mothers, 0.4% had smoking habits. Details of the socio-economic variables are shown in Table 4.

**Table 4: Socio-economic variables of the mothers**

<b>Socioeconomic details</b>	<b>Yes</b>	<b>No</b>
Employment	34 (14.3%)	204 (85.7%)
Smoking	1 (0.4%)	237 (99.6%)
Alcohol consumption	2 (0.8%)	236 (99.2%)
Marital status		
Single	215 (90.3%)	
Married	23 (9.7%)	

**3.4 Previous macrosomic history**

Thirty five (14.7%) mothers gave previous history of delivering macrosomic infants. All mothers delivered at term. Neonatal outcome showed that 227(95.4%) were live births, 10 (4.2%) stillbirths and one (0.4%) neonatal death.

**3.5 Co-morbidities**

Co-morbidities are listed in Table 5. Four (1.7%) had asthma, twenty one (8.8%) had hypertensive complications of pregnancy, two (0.8%) had thyroid disorder, three (1.3%) had diabetes and two (0.8%) had tuberculosis successfully treated.

**Table 5: Co-morbidities**

<b>Co-morbidities (n=33)</b>	<b>Number (n)</b>	<b>Percentage (%)</b>
Asthma	4	1.7
Anaemia	1	0.4
Peripartum cardiomyopathy	1	0.4
Hypertensive complications of pregnancy	21	8.8
Thyroid disorder	2	0.8
Epilepsy	1	0.4
Diabetes	3	1.3

### **3.6 Maternal outcomes**

Labour was induced in 13.4% of the mothers. Fourteen(5.9%) mothers experienced prolonged second stage of labour and shoulder dystocia occurred in 2.4% of the deliveries.

#### **3.6.1 Mode of delivery**

One hundred and fifty three (64.3%) delivered by CS, 109 (71.2%) by emergency CS and 44 (28.8%) by elective CS. Eighty five (35.7%) delivered by normal vaginal delivery. Elective episiotomy was done in most cases of vaginal deliveries. The three main indications for CS were previous CS (29.4%), fetal distress (27.5%) and cephalo-pelvic disproportion (14.4%). Indications for CS are shown in Table 6.

**Table 6: Indications for CS**

Indications for CS (n=153)	Number (n)	Percentage (%)
<b>Emergency CS (n=109)</b>		
Fetal distress	42	27.5
Cephalo pelvic disproportion	22	14.4
Poor progress	8	5.2
Ante partum haemorrhage	4	2.6
Previous CS	11	7.2
MSL 2/3	6	3.9
Failed induction	3	1.9
Failed VBAC	3	1.9
Breech	5	3.3
Delayed 2 <sup>nd</sup> stage	3	1.9
Gestational hypertension	1	0.7
Preeclampsia	1	0.7
<b>Elective CS (n=44)</b>		
Previous CS	34	22.2
Failed induction of labour	4	2.6
Big baby	6	3.9

**3.6.2 Maternal complications**

Overall, 58 patients (24.4%) presented with maternal complications. First degree perineal tears occurred in 9 (10.6%) women, 2nd degree in 19 (22.4%), cervical lacerations in 1 (0.4%). Twenty nine (12.2%) experienced postpartum hemorrhage. (Table 7)

**Table 7. Complications experienced by mothers following delivery of macrosomic babies either by normal vaginal delivery and caesarean delivery**

Normal vaginal delivery(n=85)	Number (n)	Percentage (%)
1 <sup>st</sup> degree tear	9	10.6
2 <sup>nd</sup> degree tear	19	22.4
3 <sup>rd</sup> degree tear	0	0
Cervical lacerations	1	1.2
Post-partum haemorrhage	12	14.1
(2 <sup>nd</sup> degree tear (n=8); cervical laceration (n=2); unknown (n=1) and episiotomy (n=1))		
<b>Caesarean delivery (n=153)</b>		
Post-partum haemorrhage	17	11.1
(elective CS (n=2) and emergency CS (n=15))		

### 3.7 Neonatal outcome

There were 237 (99.6%) live birth infants and one (0.4%) stillbirth. There was a preponderance of male infants with macrosomia with the male to female ratio of 2.0 to 1. One hundred and fifty three (64.3%) of the infant were male and 85 (35.7%) were female.

Birth weight ranged between 4000 and 5500 g. The majority (92%) of newborns had a birth weight between 4000 and 4499 g (Table 8), the mean and median birthweight was 4201 ± 201.8 g and 4160 g respectively. Subgroup analysis showed that there was no difference in the mean birth weight of macrosomic babies delivered by CS compared to macrosomic babies delivered vaginally (4210.3 ± 212.5 g vs 4178.5 ± 172.0g; p=0.2).

**Table 8. Frequency of macrosomia according to birth weight (data presented as number (n) and percentage (%), (n = 238).**

<b>Variable</b>	<b>Number (n)</b>	<b>Percentage (%)</b>
<b>Birthweight (gm)</b>		
4000 – 4499	219	92.0
4500 – 4999	17	7.2
≥ 5000	2	0.8
<b>Sex of newborn</b>		
Male	153	64.3
Female	85	35.7

The 5 minute Apgar score was greater than 7 in 98.8% of cases. Eighty (33.8%) macrosomic infants experienced complications (Table 9). Two hundred and thirty seven (99.6%) newborns were admitted to nursery for observations and as a precautionary measure for a median duration of 1 day (range 1–11). Twenty (8.4%) infants were resuscitated. Commonly observed complications were respiratory distress (3.4%), hypoglycemia (18.6%) and neonatal jaundice (5.1%).The stillbirth rate in the macrosomic infants was 0.4%, but no maternal deaths occurred. One of the macrosomic infants died at two years.

**Table 9: Neonatal complications observed in macrosomic infants**

Neonatal complications	Number (n)	Percentage (%)
Meconium stained liquor (2/3)	3	1.3
Erbs palsy	2	0.8
Birth trauma	2	0.8
Transient tachypnea of the newborn	3	1.3
Cardiac abnormality	1	0.4
Sepsis	2	0.8
Hypoglycemia	44	18.6
Respiratory distress syndrome	8	3.4
Neonatal jaundice	12	5.1
Rapid plasma reagin exposure	1	0.4
Neonatal seizures	2	0.8

No correlation was found between the weight of the newborn and the different parameters. However correlation was found between weight of newborn and gestational age at delivery ( $R=0.172$ ;  $p=0.008$ ). Moreover, macrosomia increased neonate hypoglycemia and CS delivery.



## Chapter 4

### 4.0 Discussion

The main risk factors for macrosomia in our study were delivery of a previous macrosomic baby, hypertensive disorders of pregnancy, male sex, BMI > 25 kg/m<sup>2</sup>, parity ≥1, diabetes and increased gestational age at delivery. This is consistent with risk factors with regards to previous delivery of macrosomic babies<sup>72, 73</sup>, postmaturity<sup>72, 74, 75</sup>, diabetes<sup>76 - 78</sup> and increased BMI<sup>79, 80</sup>.

It has been reported that 38 – 40% of macrosomic babies are born to mothers with at least one identifiable risk factor<sup>81</sup>. Strehlow et al (2007) in this study reported that fewer than 40% of mothers had at least one risk factor for macrosomia<sup>82</sup>. In addition, in contrast to findings in other studies, maternal age and parity<sup>17, 81, 83</sup>, were not significantly associated with macrosomic deliveries in our study. This may be due to the small size of the study population or the influence of genetic, racial or ethnic factors<sup>22</sup>.

Diabetes, pre-existing or gestational diabetes has been reported to be between 1-2% in the mothers of macrosomic babies<sup>84</sup> with incidence increasing to 5–7% with births of 4500 g and greater<sup>81, 85</sup>. Some studies have reported incidence of diabetes as high as 12.7 -19.5 %<sup>1, 86</sup>. In our study, 2.1% of our patients who delivered macrosomic babies had pre-existing diabetes and gestational diabetes.

The maternal complications were high in our audit compared to other studies. The overall maternal complications in this study was 24.4% (n=58) which is much higher than the reported overall rate of 3.1 – 7.3%<sup>87, 88</sup>. Main maternal complications in this study were postpartum hemorrhage, perineal tears and cervical lacerations in 25.2%, 33% and 1.2% respectively versus 1.2%, 1.7% and 0.7% in an alternate study<sup>88</sup>. However, another study reported postpartum haemorrhage and perineal tears in 17% and 37% patients respectively<sup>87</sup>. Perineal tears and postpartum hemorrhage increases 2 and 3-5 fold respectively in macrosomic deliveries<sup>37, 89</sup>.

The overall complications in our macrosomic infants was 33.6% (n=80) in this study which is in accordance with other studies<sup>90, 91</sup>. Complication rates as low as 5.3- 16%<sup>1, 43, 92, 93</sup> and high as 44.3 – 88% have been reported<sup>10, 75</sup>. The frequency of neonatal hypoglycaemia was the most common complications reported in majority of the studies. In our study neonatal hypoglycemia occurred in 18.6% cases compared to 34% in another study<sup>94</sup>.

Stillbirth rate (0.4%) is much lower than reported in other studies, 6 – 12%<sup>95, 96</sup>. The low stillbirth rate in this study is similar to rate in a recent study, 1.3%<sup>86</sup>. The low stillbirth rate was probably due to knowledgeable anticipation and astute supervision with timely decision on the labour and delivery process and was vital to a desirable outcome.

The incidence of fetal macrosomia in our study was 3.4% which was similar to other studies<sup>15, 86</sup>, lower than the rates of 5.5- 10% reported elsewhere<sup>73, 74, 97, 98</sup> but higher than 1.3 – 2.3%<sup>75, 99</sup>. These differences in incidence may be due to differences in the definition of fetal macrosomia, differences in geographical and socioeconomic factors of the study population.

Shoulder dystocia, one of the main perinatal difficulties with the delivery of macrosomic babies, occurs infrequently with an incidence ranging from 0.2–9.5% of all vaginal deliveries<sup>86, 100</sup>. In an earlier study, El Fekih et al (2011) reported shoulder dystocia occurred in 1.9% of all vaginal deliveries<sup>101</sup>. In our study, shoulder dystocia was noted in 2.4% cases. Labour was induced in 13.4%, probably for maternal - fetal reasons such as hypertension, diabetes or oligohydramnios.

The birthweights of the new born was between 4000 and 4499 g in 92% of cases; 7.2% between 4500-4999g and 0.8% for 5000g and above. Bekdas et al (2013) reported 88% of the macrosomic infants had birth weights between 4000-4499g, 11% between 4500-4999g and 1% 5000g and above<sup>102</sup>. In the study of Demiroren et al (2008), these rates were 68%, 24% and 8% respectively<sup>103</sup>, and in the study of Akin et al (2010) these rates were 80%, 17% and 3% respectively<sup>104</sup>. The same results were reported by most authors<sup>10, 105</sup>. Fetal sex influences macrosomia potential. Male infants weigh more than female infants at any gestational age. Recent studies have confirmed this association<sup>106</sup>. In our study, sex of the infant influenced the birth weight, macrosomia was more dominant in male with 64%, and this is consistent with other authors<sup>10, 107</sup>. Previous history of macrosomic baby is the main maternal risk factor to macrosomia<sup>85, 108</sup>. It has 95% positive predictive value for macrosomia<sup>109</sup>. In our study, 14.16% of women had a past history of macrosomia. Other studies have shown rates as high as 25.9% or more<sup>1, 18, 86, 110, 111</sup>.

Multiparity  $\geq 3$  has been associated with macrosomia<sup>14, 101, 112, 113</sup>. This study did not find this association, majority of the macrosomic babies were born to para 1 and 2. Body mass index more or equal to 25 has been shown by several authors to be a risk factor for macrosomia<sup>18, 110, 114 - 117</sup>. Our study corroborate the BMI  $\geq 25$  as a risk factor

According to Kraïem et al (2004) CS is justified in all cases of fetal weight estimation greater than 4500 g<sup>118</sup>. Many studies reported a higher rate of vaginal delivery compared to caesarean delivery when macrosomia is concerned<sup>86, 101, 108, 119</sup>.

Caesarean section delivery rate of 64.3% was high in our study compared to other studies<sup>86, 101, 108</sup>. In our study, the high CS rate was as a result of an increased number of women with previous CS and our study site policy was to deliver mothers with previous CS carrying a fetus weighing  $\geq$  of 3400 g by CS.

#### **4.1 Limitations**

This being a retrospective study, the following were observed: The history of previous fetal macrosomia in the patients or their relations was not documented in most of the files of the patients.

#### **4.2 Conclusion**

The prevalence of macrosomia was 3.4%. Main risk factors for macrosomia were previous history of macrosomia, male sex, hypertensive disorders of pregnancy, body mass index  $\geq 25$ , para 1 and 2, diabetes and higher gestational age at delivery. Mother and neonate are at increased risk of complications.

#### **4.3 Recommendations**

1. Long term follow up of macrosomic infants are recommended
2. Management of suspected macrosomia should be individualized with the aim to minimize maternal and fetal complications
3. Regular obstetric drills should be conducted
4. A study comparing the incidence of macrosomia of our diverse population in our setting is needed

## Chapter 5: References

1. Najafian M and Cheraghi M. Occurrence of Fetal Macrosomia Rate and Its Maternal and Neonatal Complications: A 5-Year Cohort Study. *ISRN Obstetrics and Gynecology*2012; (2012):ArticleID 353791,5pages<http://dx.doi.org/10.5402/2012/353791>.
2. Pedersen J, Bojsen-Moller B, Poulsen H. Blood sugar in newborn infants of diabetic mothers. *Acta Endocrinol (Copenh)* 1954; 15(1):33-52.
3. Steinke J, Driscoll SG. The extractable insulin content of pancreas from fetuses and infants of diabetic and control mothers. *Diabetes*. 1965;14(9):573-578.
4. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, et al. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med* 2008;358(19):1991-200
5. Lindsay RS. Many HAPO returns: maternal glycemia and neonatal adiposity: new insights from the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study. *Diabetes*2009; 58: 302-303.
6. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S. Births: Final data for 2004. *Natl Vital Stat Rep* 2006; 55:1–101.
7. Heiskanen N, Raatikainen K, Heinonen S. Fetal macrosomia – A continuing obstetric challenge. *Biol Neonate* 2006; 90:98–103.

8. Ng SK, Olog A, Spinks AB, Cameron CM, Searle J, McClure RJ. Risk factors and obstetric complications of large for gestational age births with adjustments for community effects: Results from a new cohort study. *BMC Public Health* 2010;10:460.
9. Chauhan SP, Grobman WA, Gherman RA, et al. Suspicion and treatment of the macrosomic fetus: a review. *American Journal of Obstetrics & Gynecology* 2005; 193(2): 332–346.
10. Mai AH and Abbassia D. The Prevalence of Fetal Macrosomia at the Specialized Hospital of Gynecology and Obstetrics of Sidi Bel Abbes (West Of Algeria). *J Nutr Food Sci* 2014; 4: 272.
11. Asplund CA, Seehusen DA, Callahan TL, Olsen C. Percentage change in antenatal body mass index as a predictor of neonatal macrosomia. *Ann Fam Med* 2008; 6:550–554.
12. Mohammadbeigi A, Farhadifar F, Soufizadeh N, Mohammadsalehi N, M Rezaiee M, and M Aghaei M. Fetal Macrosomia: Risk Factors, Maternal, and Perinatal Outcome. *Ann Med Health Sci Res* 2013; 3(4): 546–550.
13. Ojule JD, Fiebai PO, Okongwu C. Perinatal outcome of macrosomic births in Port Harcourt. *Niger J Med* 2010; 19(4):436–440.
14. Abena Obama MT, Shasha VW, Fodjo J, et al. Perinatal outcome of macrosomic births in Port Harcourt. *W Afr Med J* 1995;14(4):249–254.

15. Essel JK, Opai-Tetteh ET. Macrosomia-maternal and fetal risk factors. *S Afr Med J* 1995; 85:43–46.
16. Ørskou J, Kesmodel U, Henriksen TB, Secher NJ. An increasing proportion of infants weigh more than 4000 grams at birth. *Acta Obstet Gynecol Scand* 2001; 80:931–936.
17. Stotland NE, Caughey AB, Breed EM, Escobar GJ: Risk factors and obstetric complications associated with macrosomia. *Int J Gynaecol Obstet* 2004; 87 (3): 220-226.
18. Kamanu CI, Onwere S, Chigbu B, et al. Fetal macrosomia in African women: a study of 249 cases. *Arch GynecolObstet*2009; 279:857–861.
19. Pates, JA, McIntire DD, Casey BM, Leveno KJ. Predicting Macrosomia. *J Ultra Med* 2008; 27 (1): 39-43
20. Walsh M and McAuliffe FM. Prediction and prevention of the macrosomic fetus *European Journal of Obstetrics & Gynecology and Reproductive Biology* 2012; 162: 125–130
21. Parikh L, Iqbal, Sara N, Jelin, A, Tefera, E, Fries, Melissa H. Fetal Macrosomia Prediction in Diabetic Gravidas: The Reliability of Third Trimester Ultrasound [27M]. *Obstetrics & Gynecology*: May 2016doi: 10.1097/01.AOG.0000483466.62586.3c

22. Okun N, Verma A, Mitchell BF, Flowerdew G. Relative importance of maternal constitutional factors and glucose intolerance of pregnancy in the development of newborn macrosomia. *Journal of Maternal-Fetal and Neonatal Medicine* 1997; 6(5): 285–290.
23. Oral E, Cagdas A, Gezer A, Kaleli S, Aydinli K, Ocer F: Perinatal and maternal outcomes of fetal macrosomia. *Eur J Obstet Gynecol Reprod Biol* 2001; 99 (2): 167-171.
24. Raio L, Ghezzi F, Di Naro E, Buttarelli M, Franchi M, Durig P, Bruhwiler H: Perinatal outcome of fetuses with a birth weight greater than 4500 g: an analysis of 3356 cases. *Euro J Obstet Gynecol Reprod Biol* 2003; 109 (2): 160-165.
25. Zhang X, Decker A, Platt RW, Kramer MS: How big is too big? The perinatal consequences of fetal macrosomia. *Am J Obstet Gynecol* 2008; 198 (5): e511-e516.
26. Bjorstad AR, Irgens-Hansen K, Daltveit AK, Irgens LM: Macrosomia: mode of delivery and pregnancy outcome. *Acta Obstet Gynecol Scand* 2010; 89 (5): 664-669.
27. Onyiriuka AN. High birth weight babies: incidence and foetal outcome in a mission hospital in Benin City, Nigeria. *Niger J Clin Pract* 2006;9:114–119.
28. Handa VL, Danielsen BH, Gilbert WM: Obstetric anal sphincter lacerations. *Obstet Gynecol* 2001; 98 (2): 225-230.

29. Boulet SL, Alexander GR, Salihu HM, Pass M. Macrosomic births in the United States: determinants, outcomes, and proposed grades of risk. *Am J Obstet Gynecol* 2003; 188:1372–1378.
30. Karimu AL, Ayoade G, Nwebube NI. Arrest of descent in second stage of labour secondary to macrosomia: a case report. *J Obstet Gynaecol Can* 2003; 25:668–670.
31. Weissmann-Brenner A, Simchen MJ, Zilberberg E, et al. Maternal and neonatal outcomes of macrosomic pregnancies. *Med Sci Monit* 2012;18:PH77–PH81.
32. Meshari AA, De Silva S, Rahman I. Fetal macrosomia – maternal risks and fetal outcome. *Int J Gynecol Obstet* 1990; 32:215–222.
33. Lim JH, Tan BC, Jammal AE, Symonds EM. Delivery of macrosomic babies: management and outcomes of 330 cases. *J Obstet Gynecol* 2002; 22:370–374.
34. Siggelkow W, Boehm D, Skala C, et al. The influence of macrosomia on the duration of labor, the mode of delivery and intrapartum complications. *Arch Gynecol Obstet* 2008; 278:547–553.
35. Koyanagi A, Zhang J, Dagvadorj A, et al. Macrosomia in 23 developing countries: an analysis of a multi-country, facility-based, cross-sectional survey. *Lancet* 2013; 381:476–483.
36. Bonnet MP, Basso O, Bouvier-Colle MH, et al. Postpartum haemorrhage in Canada and France: a population-based comparison. *PLoS One* 2013; 8:e66882.



37. Mitanchez D, Yzydorczyk C, Simeoni U. What neonatal complications should the pediatrician be aware of in case of maternal gestational diabetes? *World J Diabetes* 2015; 6(5): 734-743
38. Twidale E, Cornell K, Litzow N, Hotchin A. Obstetric anal sphincter injury risk factors and the role of the mediolateral episiotomy. *Aust N Z J Obstet Gynaecol* 2013; 53:17–20.
39. King JR, Korst LM, Miller DA, Ouzounian JG. Increased composite maternal and neonatal morbidity associated with ultrasonographically suspected fetal macrosomia. *J Matern Fetal Neonatal Med* 2012; 25:1953–1959.
40. Hopkins LM, Caughey AB, Glidden DV, Laros RK Jr. Racial/ethnic differences in perineal, vaginal and cervical lacerations. *Am J Obstet Gynecol* 2005;193:455–9.
41. Gregory KD, Henry OA, Ramicone E, Chan LS, Platt LD: Maternal and infant complications in high and normal weight infants by method of delivery. *Obstet Gynecol* 1998; 92 (4 Pt 1): 507-513.
42. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No 42 Shoulder dystocia. 2nd ed. London, UK: Royal College of Obstetricians and Gynaecologists; 2012. Available from: <http://www.rcog.org.uk/womens-health/clinical-guidance/shoulder-dystocia-green-top-42>. Accessed July 5, 2016.
43. Cheng YK, Lao TT, Sahota DS, Leung VK, Leung TY. Use of birth weight threshold for macrosomia to identify fetuses at risk of shoulder dystocia among Chinese populations. *Int J Gynaecol Obstet* 2013; 120:249–253.
44. Esakoff TF, Cheng YW, Sparks TN, Caughey AB. The association between birthweight 4000g or greater and perinatal outcomes in patients with and without gestational diabetes mellitus. *Am J Obstet Gynecol* 2009; 200(6):672.e1–e4.

45. Overland EA, Vatten LJ, Eskild A. Risk of shoulder dystocia: associations with parity and offspring birthweight. A population study of 1 914 544 deliveries. *Acta Obstet Gynecol Scand* 2012; 91:483–488.
46. Foad SL, Mehlman CT, Ying J. The epidemiology of neonatal brachial plexus palsy in the United States. *J Bone Joint Surg Am* 2008; 90:1258–1264
47. Torki M, Barton L, Miller DA, Ouzounian JG. Severe brachial plexus palsy in women without shoulder dystocia. *Obstet Gynecol* 2012; 120:539–541.
48. Leung TY, Chung TKH. Severe chronic morbidity following childbirth. *Best Pract Res Clin Obstet Gynaecol* 2009; 23:401–423.
49. Bryant DR, Leonardi MR, Landwehr JB, Bottoms SF. Limited usefulness of fetal weight in predicting neonatal brachial plexus injury. *Am J Obstet Gynecol* 1998; 179(3 Pt 1):686–689.
50. Kolderup LB, Laros RK, Musci TJ. Incidence of persistent birth injury in macrosomic infants: association with mode of delivery. *Am J Obstet Gynecol* 1997; 177:37–41.
51. Melendez J, Bhatia R, Callis L, Woolf V, Yoong W. Severe shoulder dystocia leading to neonatal injury: a case control study. *Arch Gynecol Obstet* 2009; 279:47–51
52. Nassar AH, Usta IM, Khalil AM, Melhem ZI, Nakad TI, Musa AAA. Fetal macrosomia ( $\geq 4500$  g): perinatal outcome of 231 cases according to the mode of delivery. *J Perinatol* 2003; 23:136–141.
53. Chibber R. Unexplained antepartum fetal deaths: what are the determinants? *Arch Gynecol Obstet* 2005; 271:286–291.

54. Mondestin MA, Ananth CV, Smulian JC, Vintzileos AM. Birth weight and fetal death in the United States: the effect of maternal diabetes during pregnancy. *Am J Obstet Gynecol* 2002; 187: 922–926.
55. Wilcox AJ. On the importance – and the unimportance – of birthweight. *Int J Epidemiol* 2001;30:1233–1241
56. Malloy MH. Size for gestation age at birth: impact on risk for sudden infant death and other causes of death, USA 2002. *Arch Dis Child Fetal Neonatal Ed.* 2007; 92:F473–F478.
57. Barker DF. The developmental origins of adult disease. *J Am Coll Nutr* 2004; 23 Suppl 6:588S–595S.
58. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. *Pediatrics* 2005;115:e290–e296
59. Silva Idos S, De Stavola B, McCormack V. Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies. *PLoS Med.* 2008; 5:e193.
60. Dudley NJ. A systematic review of the ultrasound estimation of fetal weight. *Ultrasound Obstet Gynecol* 2005; 25:80–89.
61. Colman A, Maharaj D, Hutton J, Tuohy J. Reliability of ultrasound estimation of fetal weight in term singleton pregnancy. *NZ Med J* 2006; 119:U2146.

62. Hoopmann M, Abele H, Wagner N, Wallwiener D, Kagan KO. Performance of 36 different weight estimation formulae in fetuses with macrosomia. *Fetal Diag Ther* 2010; 27:204–213.
63. Hart NC, Hilbert A, Meurer B, et al. Macrosomia: a new formula for optimized fetal weight estimation. *Ultrasound Obstet Gynecol* 2010; 35:42–47.
64. Nesbitt TS, Gilbert WM, Herrchen B. Shoulder dystocia and associated risk factors with macrosomic infants born in California. *Am J Obstet Gynecol* 1998; 179:476–480.
65. Leung TY, Leung TN, Sahota DS, et al. Trends in maternal obesity and associated risks of adverse pregnancy outcomes in a population of Chinese women. *Br J Obstet Gynecol* 2008; 115:1529–1537.
66. Getahun D, Ananth CV, Peltier MR, Salihu HM, Scorza WE. Changes in pre pregnancy body mass index between the first and second pregnancies and risk of large-for-gestational-age birth. *Am J Obstet Gynecol* 2007; 196:530–538.
67. Horvath K, Koch K, Jeitler K, et al. Effects of treatment in women with gestational diabetes mellitus: systematic review and meta-analysis. *Br Med J* 2010; 340:c1395.
68. Irion O, Bouvain M. Induction of labour for suspected fetal macrosomia. *Cochrane Database Syst Rev*. 2002; 2:CD000938.

69. National Institute for Health and Clinical Excellence. Diabetes in pregnancy. Management of diabetes and its complications from pre-conception to the postnatal period. Clinical Guideline 63. London, UK: National Institute for Health and Clinical Excellence; 2008. Available from: <http://www.nice.org.uk/nicemedia/pdf/CG063Guidance.pdf>. Accessed July 5, 2016.
70. Rouse DJ, Owen J, Goldenberg RL, Cliver SP. The effectiveness and costs of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound. *J Am Med Assoc* 1996; 276:1480–1486.
71. Sokol RJ, Blackwell SC; American College of Obstetricians and Gynecologists. Committee on Practice Bulletins – Gynecology. ACOG practice bulletin: Shoulder dystocia. Number 40, Nov 2002. (Replaces practice pattern number 7, Oct 1997). *Int J GynecolObstet* 2003; 80:87–92.
72. WHO. Report of a WHO Expert Committee. Geneva: WHO; 1995. Physical Status: The Use and Interpretation of Anthropometry. (Who Technical Report Series 854).
73. Mutihir JT, Ujah A. Postmaturity and fetal macrosomia in Jos, Nigeria. *Annals of African Medicine*, 2005;4(2):72-76.
74. Vinturache AE, Chaput KH, Tough SC Pre-pregnancy body mass index (BMI) and macrosomia in a Canadian birth cohort. *J Matern Fetal Neonatal Med* 2016; 6:1-8.
75. Olorok OE, Onakewhor JU, Aderoba AK. Determinants and outcome of fetal macrosomia in a Nigerian tertiary hospital *Niger Med J*. 2015 Nov-Dec; 56(6): 411–415.

76. Said AS and Manji KP. Risk factors and outcomes of fetal macrosomia in a tertiary centre in Tanzania: a case-control study. *BMC Pregnancy and Childbirth* 2016; 16:243
77. ChoukemS-P, Njim T, Atashili J, Hamilton-Shield JP, Robinson Mbu R. High birth weight in a suburban hospital in Cameroon: an analysis of the clinical cut-off, prevalence, predictors and adverse outcomes. *BMJ Open* 2016;6:e011517
78. Levy A, Wiznitzer A, Holcberg G, Mazor M, Sheiner E. Family history of diabetes mellitus as an independent risk factor for macrosomia and cesarean delivery. *J Matern Fetal Neonatal Med* 2010 ; 23(2):148-52.
79. Kc K, Shakya S, Zhang H. Gestational diabetes mellitus and macrosomia: a literature review. *Ann Nutr Metab.* 2015;66 Suppl 2:14-20
80. Gaudet L, Ferraro ZM, Wen SW, Walker M. Maternal obesity and occurrence of fetal macrosomia: a systematic review and meta-analysis. *Biomed Res Int.* 2014;2014:640291.
81. NkwabongE. Maternal and neonatal complications of macrosomia. *Trop Doct.* 2014 Oct;44(4):201-4
82. Boyd ME, Usher RH, Maclean. Fetal macrosomia, prediction, risk proposed management. *ObstetGynaecol*1983; 61(5) 715-22.

83. Strehlow S, Uzelac P. Complications of labour and delivery. In: Decherney AH, Nathan L, Goodwin TM, Laufer N, editors. *Current Obstetrics and Gynecology, Diagnosis and Treatment*. New York: The McGraw-Hill Companies, Inc.; 2007. pp. 432–40.
84. Yadav Hand Lee N. Factors influencing macrosomia in pregnant women in a tertiary care hospital in Malaysia. *J Obstet Gynaecol Res* 2014; 40(2):439-44.
85. Sacks DA. Fetal macrosomia and gestational diabetes: what's the problem? *Obstetrics and Gynecology* 1993; 81(5): 775–781
86. Modanlou HD, Dorchester WL, Thorosian A, Freeman RK. Macrosomia: maternal, fetal, and neonatal implications. *Obstetrics and Gynecology* 1980; 55 (4): 420–424
87. Osaikhuwuomwan J, Osemwenkha A, Orukpe G. Macrosomic births in a tertiary public hospital: a survey of maternal characteristics and fetal outcome. *Ethiop J Health Sci*. 2016; 26(1): 31-36
88. Fuchs F, Bouyer J, Rozenberg P, Marie-Victoire Senat. Adverse maternal outcomes associated with fetal macrosomia: what are the risk factors beyond birthweight ? *BMC Pregnancy Childbirth*. 2013; 13: 90.
89. Alsammani MA and S. Ahmed SR. Fetal and maternal outcomes in pregnancies complicated with fetal macrosomia, *North American Journal of Medical Sciences* 2012; 4(6): 283–286.

90. Lazer S, Biale Y, Mazor M. Complications associated with the macrosomic fetus. *Journal of Reproductive Medicine for the Obstetrician and Gynecologist* 1986; 31(6): 501–505
91. Zonana-Nacach A, Baldenebro-Preciado R, Ruiz-Dorado MA. The effect of gestational weight gain on maternal and neonatal outcomes. *Salud Publica Mex.* 2010; 52:220–225.
92. Gomez HL, Martinez ML, Rodriguez ZM. Clinical and epidemiological profile of diabetes mellitus in pregnancy, Isle of Youth, 2008. *Med Rev.* 2011; 13:29–34
93. Sabah H, Al-Atwani A, Ali A. Obaid AA. The frequency of hypoglycemia in macrosomic neonates in Amarah governorate, Iraq. *Al-Kindy College Medical Journal* 2015; 11(1): 78-80
94. Paunekar VM and D Rajashree D. Neonatal Complications of Gestational Diabetes Mellitus. *Sch. J. App. Med. Sci.*, 2015; 3(8D):2985-2988
95. Aranha A, MalabuUH, Vangaveti V, ES, Tan YM, SanglaKS. Macrosomia in non-gestational diabetes pregnancy: glucose tolerance test characteristics and fetomaternal complications in tropical Asia Pacific Australia. *Asian Pac J Trop Biomed.* 2014; 4(6): 436–440.
96. Ndiaye-O, Gbaguidi-A, BA-M. Newborn infant with macrosomia: etiologic factors and prenatal complications. *Dakar Med J* 1997;42(2):159-161



97. Mahony R, Walsh C, Foley ME, Daly L, O'Herlihy C. Outcome of second delivery after prior macrosomic infant in women with normal glucose tolerance. *Obstet Gynecol* 2006; 107: 857-862.
98. Luhete PK, Mukuku O, Kiopin PM, Tambwe AM, Kayamba PK. Fetal macrosomia in Lubumbashi: risk factors and maternal and perinatal prognosis. *Pan Afr Med J*. 2016; 6; 23:166. [Article in French] English abstract
99. García-De la Torre JI, Rodríguez-Valdez A, Delgado-Rosas A. [Risk factors for fetal macrosomia in patients without gestational diabetes mellitus]. *Ginecol Obstet Mex*. 2016; 84 (3):164-71. [Article in Spanish] English Abstract
100. Gherman RB. Shoulder dystocia: an evidence-based evaluation of the obstetric nightmare. *Clin Obstet Gynecol* 2002; 45: 345-362.
101. ElFekih C, Mourali M, Ouerdiane N, Oueslati S, HadjHassine A, Chaabène M. Maternal and fetal outcomes of large fetus delivery: A comparative study. *La Tunisie Medicale* 2011; 89(6): 553 – 556
102. Bekdas M, Demircioğlu F, Göksügür SB, Ekici A, Kısmet E. A cross-sectional study of non-diabetic macrosomic infants. *Sri Lanka Journal of Child Health*, 2013; 42(2): 76-80
103. Demiroren K, Demiroren S, Yuksekkaya HA, Koc H. Complications in macrosomic infants of nondiabetic mothers. *Fırat University Medical Journal of Health Sciences* 2008; 22(2): 81–6.

104. Akin Y, Comert S, Turan C ve ark. Macrosomic newborns: a 3-year review. Turkish Journal of Pediatrics 2010; 52: 378-83.
105. El Hak MS. Macrosomie foetale. Médecine, Casablanca, Université Hassan II, Thèse N°20,84; 2006(English abstract)
106. Di Renzo GC, Rosati A, Sarti RD, Cruciani L, Cutuli AM. Does fetal sex affect pregnancy outcome? Gender Medicine 2007; 4(1): 19–30
107. Touhami Elouazzani F, La macrosomie A. La macrosomie: à propos de 255 cas. Macrosomia: About 255 cases. Journal de pédiatrie et de puériculture 2012; 25: 97-101.
108. Panel P, de Meeus JB, Yanoulopoulos B, Deshayes M, Magnin G. Delivery of large infants. Management and results of 198 cases. J Gynecol Obstet Biol Reprod 1991; 20: 729-736.
109. ACOG Practice Bulletin No.22: Fetal Macrosomia. American College of Obstetricians and Gynecologists, Washington DC 2000.
110. Nkwabong E and Tangho GRN. Risk Factors for macrosomia. J Obstet Gynaecol India 2015; 65(4): 226–229.

111. Haji-Ebrahim-Tehrani F, Kazemi H, Kordi M. Prevalence and outcome of the macrosomic infants. *Acta Medica Iranica* 2007; 45(6): 505–509.
112. Bérard J, Dufour P, Vinatier D et al. Fetal macrosomia: risk factors and outcome. A study of the outcome concerning 100 cases >4500 g. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 1998; 77(1): 51–59.
113. Ehrenberg HM, Mercer BM, Catalano PM. The influence of obesity and diabetes on the prevalence of macrosomia. *American Journal of Obstetrics and Gynecology* 2004; 191 (3): 964–968.
114. Viswanathan M, Siega-Riz AM, Moos MK, Deierlein A, Mumford S, Knaack J, et al. Outcomes of maternal weight gain. *Evid Rep Technol Assess (Full Rep)* 2008; 1:1–223.
115. Addo VN. Body mass index, weight gain during pregnancy and obstetric outcomes. *Ghana Med J.* 2010; 44:64–9.
116. Sekhavat L, Golestan M, Fallah R. Evaluation of excessive pregnancy weight gain effect in non-diabetic women with normal pre-pregnancy BMI on macrosomia of neonates. *Acta Med Iran* 2011; 49:21–4.
117. Bergmann RL, Richter R, Bergmann KE, et al. Secular trends in neonatal macrosomia in Berlin: influences of potential determinants. *Paediatr Perinat Epidemiol* 2003; 17(3):244–249.

118. Kraïem J, Chiha N, Bouden S, Ounaïssa F, Falfoul A. The delivery of macrosomic infants weighing 4500 g and more. A report of 61 cases. *La Tunisie Medicale* 2004; 82(7): 656–661
119. Diani F, Moscatelli C, Toppano B, Turinetto A. Fetal macrosomia and mode of delivery. *Minerva Ginecologica* 1995; 47:77–82.

## Chapter 6: Appendices

### Appendix 1: Data Sheet

1. Study No:
2. Date Of Delivery:
3. Maternal BMI:
4. Age:
5. Parity:
6. Gravidity:
7. Booked :( Y=1,N=2)
8. Booking Gestational Age:
9. Gestational Age at delivery:
10. Number of Antenatal visits:
11. Ethnic Group: ( African=1, Indian=2, Coloured=3,white=4)
12. RH:
13. RPR: (+ve=1, -ve=2)
14. HB:
15. HIV Status(neg=1, pos=2)
16. Maternal obstetric condition: ( Overt diabetic=1, gestational diabetic=2, Other=3)

### 17. Socioeconomic

- 17.1 Employed: (Y=1, N=2)
- 17.2 Cigarette smoke: (Y=1, N=2)
- 17.3 Alcohol use:(Y=1,N=2)
- 17.4 Marital Status: ( single=1, married=2, divorced=3, engaged=4)

**18. Past Obstetric History**

18.1 Previous big baby:(Y=1,N=2)

18.2 Gest Age at delivery:

18.3 Outcome:( 1=alive, 2=SB, 3=ENND, 4=LNND)

**19. Past medical history**

( Diabetes mellitus=1, Thyroid disorder Anaemia=3, Hypertension=4,  
Cardiac disease=5, Epilepsy=6)

**20. Maternal Outcomes**

20.1 Induction of labour:(Y=1, N=2)

20.2 Prolonged second stage:( Y=1,N=2)

20.3 Elective caesarean delivery

20.4 Emergency caesarean delivery

20.5 Instrumental vaginal delivery

20.6 Shoulder dystocia

20.7 Second and third degree perineal tear

20.8 Fourth degree perineal tear

20.9 Post-partum haemorrhage

20.10 Length of stay>3 days

21. **Foetal outcome**

21.1 Male gender

21.2 Birth weight

21.3 Apgar's:

21.3.1 1<sup>st</sup> min

21.3.2 5<sup>th</sup> min

21.4 Outcome:( 1=alive, 2=SB, 3= ENND, 4=LNND)

21.5 Congenital abnormality:( Y=1, N=2)

21.6 Resuscitation

21.7 Intensive care unit/nursery

21.8 Neonatal complications:( neonatal seizures=1, Erb's palsy=2  
( birth trauma=3, other=4)

21.9 Number of days in nursery: